Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
All content for HealthTech Israel Podcast is the property of Chen Sirkis and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
Michal Geva, Co-Founder and Managing Partner, Triventures
HealthTech Israel Podcast
56 minutes
4 years ago
Michal Geva, Co-Founder and Managing Partner, Triventures
Michal Geva is the managing partner and co-founder of Triventures. Michal is one of the most prominent investors in Israel's MedTech and digital health scene. She resides on the boards of many companies and has accumulated a track record of multiple exits, including 6over6, Orthospace, and Aprica.01:01 Where did your passion for health tech actually start? 03:42 Why did you decide to found Triventures?09:34 Could you expand a little bit on how your model works? 11:52 Do you build a ...
HealthTech Israel Podcast
Alon Ben-Noon is the Co-founder and CEO, of NeuroSense Therapeutics, a drug development company focusing on the treatment of ALS and other neurodegenerative diseases. *This interview was conducted in January of 2022*Since the interview, NeuroSense successfully concluded additional biomarker experiments of ALS and Alzheimer's disease. In addition, the company commenced a Phase IIb clinical trial in ALS (Paradigm Study) and enrolled several patients with the aim to complete enrollment by ...
